Myovant Sciences (MYOV) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Myovant Sciences (NYSE:MYOV) announced its earnings results on Thursday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.06), Fidelity Earnings reports.

MYOV stock traded down $2.17 on Friday, reaching $19.12. 4,115 shares of the company traded hands, compared to its average volume of 60,154. Myovant Sciences has a one year low of $11.30 and a one year high of $27.45. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.73. The firm has a market cap of $1.56 billion, a PE ratio of -7.90 and a beta of 0.12.

Several research analysts have recently issued reports on MYOV shares. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. Goldman Sachs Group started coverage on Myovant Sciences in a research report on Friday, October 26th. They issued a “neutral” rating and a $25.00 target price for the company. JPMorgan Chase & Co. started coverage on Myovant Sciences in a research report on Thursday, September 13th. They issued an “overweight” rating and a $39.00 target price for the company. Finally, Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Friday. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Myovant Sciences currently has an average rating of “Buy” and a consensus price target of $29.20.

In related news, Director Mark Altmeyer acquired 3,500 shares of Myovant Sciences stock in a transaction that occurred on Saturday, November 17th. The stock was bought at an average price of $13.38 per share, with a total value of $46,830.00. Following the transaction, the director now directly owns 3,500 shares in the company, valued at $46,830. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.10% of the stock is owned by company insiders.

WARNING: “Myovant Sciences (MYOV) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.wkrb13.com/2018/11/09/myovant-sciences-myov-posts-quarterly-earnings-results-misses-estimates-by-0-06-eps.html.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Recommended Story: Return on Equity (ROE)

Earnings History for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply